<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02599116</url>
  </required_header>
  <id_info>
    <org_study_id>MMC 2015-53</org_study_id>
    <nct_id>NCT02599116</nct_id>
  </id_info>
  <brief_title>Gastrointestinal Microbiome Study of Appendiceal Cancer</brief_title>
  <official_title>A Cohort Study of the Gastrointestinal Microbiome in Appendiceal Cancer With Peritoneal Spread</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mercy Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mercy Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study analyzes the gastrointestinal microbiome of appendiceal cancer patients with
      peritoneal spread scheduled to undergo cytoreductive surgery with hyperthermic
      intraperitoneal chemotherapy (CRS/HIPEC). Participants will provide fecal samples pre- and
      post-operatively.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Analysis of the human microbiome is an attempt to define how changes in the human microbiome
      are associated with health or disease.

      Eligible participants scheduled to undergo cytoreductive surgery with hyperthermic
      intraperitoneal chemotherapy (CRS/HIPEC) for appendiceal cancer will provide fecal samples
      pre- and post-operatively. Investigators will analyze potential changes in the
      gastrointestinal microbiome and make comparisons to an age-matched healthy sample.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine whether the intestinal microbiome of patients with appendiceal tumors with peritoneal carcinomatosis differs from that of a healthy, age-matched cohort</measure>
    <time_frame>36 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compare the gut microbiome of appendiceal tumors by histopathology</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Identify potential biomarkers associated with appendiceal tumors</measure>
    <time_frame>36 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Identify alterations in the gut microbiome post-CRS/HIPEC</measure>
    <time_frame>36 months</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Pseudomyxoma Peritonei</condition>
  <condition>Appendiceal Neoplasm</condition>
  <condition>Cancer, Appendiceal</condition>
  <arm_group>
    <arm_group_label>Microbiome cohort</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Pre-operative (baseline) bio-specimen collection (fecal sample) and completion of two food and lifestyle questionnaires.
Six to twelve weeks following cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC), post-operative bio-specimen collection (fecal sample) and completion of two food and lifestyle questionnaires
Six to twelve months following cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC), post-operative bio-specimen collection (fecal sample) and completion of two food and lifestyle questionnaires</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Bio-specimen collection</intervention_name>
    <description>Collection of bio-specimens (fecal sample) at 3 different time points One pre-operative collection, Two post-operative collections</description>
    <arm_group_label>Microbiome cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire</intervention_name>
    <description>Completion of lifestyle and food questionnaires (2) at each bio-specimen collection timepoint</description>
    <arm_group_label>Microbiome cohort</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of appendiceal cancer with peritoneal spread

          -  Candidate for cytoreductive surgery with hyperthermic intraperitoneal chemotherapy
             (CRS/HIPEC)

          -  ≥18 and ≤ 80 years of age

          -  Eastern Cooperative Oncology Group performance status score of ≤2/Karnofsky
             performance status (KPS) ≥70%

          -  Signed Institutional Review Board approved informed consent

        Exclusion Criteria:

          -  &lt;18 years of age

          -  Pregnant women

          -  Concurrent severe medical problems unrelated to malignancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Armando Sardi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mercy Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michelle Sittig, RN</last_name>
    <phone>410-332-9294</phone>
    <email>msittig@mdmercy.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mercy Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://americangut.org/</url>
    <description>The American Gut Project is an open-source project to understand the microbial diversity of the human gut.</description>
  </link>
  <results_reference>
    <citation>Gilbreath JJ, Semino-Mora C, Friedline CJ, Liu H, Bodi KL, McAvoy TJ, Francis J, Nieroda C, Sardi A, Dubois A, Lazinski DW, Camilli A, Testerman TL, Merrell DS. A core microbiome associated with the peritoneal tumors of pseudomyxoma peritonei. Orphanet J Rare Dis. 2013 Jul 12;8:105. doi: 10.1186/1750-1172-8-105.</citation>
    <PMID>23844722</PMID>
  </results_reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 4, 2015</study_first_submitted>
  <study_first_submitted_qc>November 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 6, 2015</study_first_posted>
  <last_update_submitted>January 24, 2018</last_update_submitted>
  <last_update_submitted_qc>January 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mercy Medical Center</investigator_affiliation>
    <investigator_full_name>Armando Sardi</investigator_full_name>
    <investigator_title>Chief Surgical Oncology at Mercy</investigator_title>
  </responsible_party>
  <keyword>cytoreductive surgery</keyword>
  <keyword>hyperthermic intraperitoneal chemotherapy</keyword>
  <keyword>microbiome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pseudomyxoma Peritonei</mesh_term>
    <mesh_term>Appendiceal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

